1991
DOI: 10.1002/hep.1840130529
|View full text |Cite
|
Sign up to set email alerts
|

Immunology and the liver

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
62
0

Year Published

1993
1993
2007
2007

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 142 publications
(62 citation statements)
references
References 97 publications
0
62
0
Order By: Relevance
“…However, other mechanisms may also contribute to impaired neutralizing antibody production in LCMV-infected mice, such as the CD8 + T cell-mediated destruction of antigen presenting cells or polyclonal B cell activation observed after infection with viscerotropic strains such as LCMV-WE [31,32]. Similar mechanisms may also operate during HIV and hepatitis B virus infections in humans, where, as in LCMV infection of mice, only non-neutralizing antibodies are induced early and there is a delayed and frequently low titered neutralizing antibody response [33,34].…”
Section: Discussionmentioning
confidence: 99%
“…However, other mechanisms may also contribute to impaired neutralizing antibody production in LCMV-infected mice, such as the CD8 + T cell-mediated destruction of antigen presenting cells or polyclonal B cell activation observed after infection with viscerotropic strains such as LCMV-WE [31,32]. Similar mechanisms may also operate during HIV and hepatitis B virus infections in humans, where, as in LCMV infection of mice, only non-neutralizing antibodies are induced early and there is a delayed and frequently low titered neutralizing antibody response [33,34].…”
Section: Discussionmentioning
confidence: 99%
“…The mechanisms responsible for the variable clinical course and outcome of HBV infection are not known. There is considerable evidence suggesting that HBV is not directly cytopathic (3), and that the hepatitis is caused by immune responses against virus-infected hepatocytes (4). In vitro studies have shown that hepatitis B surface antigen (HBsAg)-and hepatitis B core antigen (HBcAg)-expressing transfectants can serve as targets for MHC class I-restricted cytotoxic T lymphocytes (CTLs) that are generated from both acute and chronic hepatitis B patients (5)(6)(7)(8)(9)(10)(11)(12).…”
Section: Introductionmentioning
confidence: 99%
“…Few or no class I and class II human leucocyte antigens (HLA) appear to be expressed by normal hepatocytes [1], It is postulated that the variable findings that have appeared in the literature in recent years may represent unrecognized immunological agents promoting the expression of HLA products at the hepatocyte membrane [2], HLA antigen expression in many liver diseases has been well documented. These include hepatitis B virus infection [3][4][5] and hepatoceilular carcinoma {HCC) [2,[5][6][7].…”
Section: Introductionmentioning
confidence: 99%